APA Corporation logo APA - APA Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 19
HOLD 27
SELL 5
STRONG
SELL
0
| PRICE TARGET: $35.00 DETAILS
HIGH: $45.00
LOW: $22.00
MEDIAN: $39.00
CONSENSUS: $35.00
DOWNSIDE: 9.79%

Stock News

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla” or the “Company”), a leader in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX-class compounds, today announced that it has executed a definitive SPV Formation, Shareholder and License Agreement (the “Definitive Agreement”) with Aluvaris Inc. (“Aluvaris”) and Diteba Inc. (“Diteba”). The Definitive Agreement establishes a jointly-owned special purpose vehicle called Restora Neurosciences (the “Restora” or the “SPV”) to lead the clinical and regulatory development of APA-01, the Company's patented novel MDXX molecule, with the explicit objective of filing a first Investigational New Drug application with the U.S. Food and Drug Administration.

May 13, 2026 04:30 AM globenewswire.com
Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings

Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings

MORRISTOWN, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced that it will share the full results of the RECONNECT, a Phase 2 trial evaluating luvesilocin in adult female patients with moderate-to-severe postpartum depression (PPD), in an oral presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2026 – Psychiatry and AI: Promises, Perils, and Pathways Forward in Miami, FL.

May 11, 2026 04:01 AM globenewswire.com
APA Corporation: Cheap Oil Stock With Suriname Optionality

APA Corporation: Cheap Oil Stock With Suriname Optionality

APA Corporation is rated Buy with a 12-month price target of $46.72, reflecting ~30% upside from current levels. APA trades at a significant valuation discount to peers, with a forward P/E of 6.7x and 3.6x EV/EBITDA, despite robust cost-saving initiatives. Cost reductions, a 10% capex cut for 2026, and stable Egyptian operations are expected to enhance FCF and support sustainability at current oil prices.

May 08, 2026 12:32 PM seekingalpha.com

Price Targets